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ABSTRACT
Background Holoprosencephaly is a spectrum of 
developmental disorder of the embryonic forebrain in 
which there is failed or incomplete separation of the 
prosencephalon into two cerebral hemispheres. To date, 
dominant mutations in sonic hedgehog (SHH) pathway 
genes are the predominant Mendelian causes, and 
have marked interfamilial and intrafamilial phenotypical 
variabilities.
Methods We describe two families in which offspring 
had holoprosencephaly spectrum and homozygous 
predicted- deleterious variants in phospholipase C eta-1 
(PLCH1). Immunocytochemistry was used to examine the 
expression pattern of PLCH1 in human embryos. We used 
SHH as a marker of developmental stage and of early 
embryonic anatomy.
Results In the first family, two siblings had congenital 
hydrocephalus, significant developmental delay and 
a monoventricle or fused thalami with a homozygous 
PLCH1 c.2065C>T, p.(Arg689*) variant. In the second 
family, two siblings had alobar holoprosencephaly 
and cyclopia with a homozygous PLCH1 c.4235delA, 
p.(Cys1079ValfsTer16) variant. All parents were 
healthy carriers, with no holoprosencephaly spectrum 
features. We found that the subcellular localisation of 
PLCH1 is cytoplasmic, but the p.(Cys1079ValfsTer16) 
variant was predominantly nuclear. Human embryo 
immunohistochemistry showed PLCH1 to be expressed 
in the notorcord, developing spinal cord (in a ventral to 
dorsal gradient), dorsal root ganglia, cerebellum and 
dermatomyosome, all tissues producing or responding to 
SHH. Furthermore, the embryonic subcellular localisation 
of PLCH1 was exclusively cytoplasmic, supporting protein 
mislocalisation contributing to the pathogenicity of the 
p.(Cys1079ValfsTer16) variant.
Conclusion Our data support the contention 
that PLCH1 has a role in prenatal mammalian 
neurodevelopment, and deleterious variants cause 
a clinically variable holoprosencephaly spectrum 
phenotype.
INTRODUCTION
Holoprosencephaly is a structural anomaly of the 
brain in which there is failed or incomplete sepa-
ration of the embryonic prosencephalon into two 
cerebral hemispheres and associated bilateral 
structures. In humans, the defect causing holo-
prosencephaly arises between the third- week and 
fifth- week postfertilisation.1 The most severe forms 
of holoprosencephaly are classified as alobar, semi-
lobar and lobar, and the greater the degree of holo-
prosencephaly, the greater the degree of intellectual 
deficit and associated congenital anomalies.2 These 
include facial anomalies (ranging from cyclopia 
and a proboscis to a single upper incisor, to none), 
central (and bilateral) cleft lip and palate, congen-
ital heart disease, preaxial polydactyly and endo-
crine deficiencies.2 3
The prevalence of holoprosencephaly is esti-
mated to be 1/250 in conceptuses and 1/16 000 
live births.4 The aetiology of human holopros-
encephaly is varied: environmental (eg, maternal 
diabetes gives a 1% risk to the fetus), chromosomal 
(the most common overall cause, an example being 
trisomy 13), Mendelian or unknown.2 Mendelian 
causes are subclassified into non- syndromic (which 
are inherited as dominant disorders) and syndromic 
(where there are additional distinctive features, and 
inheritance can be either dominant or recessive).2 
Many of the 14 genes known to cause holoprosen-
cephaly are involved in the sonic hedgehog (SHH) 
signalling pathway.5 6
The study of families with genetic form of holo-
prosencephaly extended the spectrum of brain 
and facial anomalies to include the milder pheno-
types. The ‘middle interhemispheric fusion variant’ 
consists of syntelencephaly (where posterior, frontal 
and parietal areas lack midline separation and/or 
lack of cleavage of the basal ganglia and thalami, 
and absence of the body of the corpus callosum). 
‘Microform holoprosencephaly’ is a much milder 
form where the brain is structurally normal, but 
there are subtle craniofacial anomalies with or 
without mild neurocognitive impairment.7–9
A marked variability of phenotype is a constant 
finding in the Mendelian disorders associated 
with holoprosencephaly, and this variability is 
seen within families, and between individuals in 
different families with the same mutation.2 10 The 
degree of phenotypical variability seen in domi-
nant disorders that cause holoprosencephaly is 
unusually marked, and this variability is also 
seen in the recessive disorder Smith- Lemli- Opitz 
syndrome (SLOs), where consistency of phenotype 
may have been expected.11 The causes of this vari-
ability are unknown but are considered related to 
three factors: the complexity of the developmental 
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pathways in which SHH participates (in consort with trans-
forming growth factor-β (TGF‐β) and fibroblast growth factor 
(FGF) pathway signalling); that otherwise harmless polymor-
phisms in holoprosencephaly- related genes could become disease 
modifiers; and that the environmental/maternal factors such as 
alcohol, diabetes and cholesterol intake and metabolism can 
affect the intracellular and intercellular environments resulting 
in altered SHH signalling.12–14
We document two families in which children have severe 
developmental delay secondary to brain malformations within 
the holoprosencephaly spectrum. We were unable to find any 
known cause of their phenotypes but did discover homozy-
gous, very rare, predicted deleterious variants in the phospho-
lipase C eta-1 (PLCH1) gene. Our clinical and molecular results 




The authors ascertained families by direct referral from the fami-
ly’s paediatricians or clinical geneticists. The family details and 
pedigrees were recorded by their physicians, informed consent 
obtained for diagnostic genetic studies and blood samples taken 
for DNA extraction. All clinical observations, studies and tests 
were performed to enable a diagnosis and guide treatment; none 
was performed solely for research purposes. Families and their 
physicians were informed of the research findings.
Molecular genetic analysis seeking pathogenic variants
The two families were separately ascertained and clinically 
investigated. No further families were notified to us after a 
GeneMatcher request; gnomAD shows no homozygous loss of 
function variants; and there were no cases reported in the DECI-
PHER study.
In each family, the affected individuals’ genomic DNA was 
extracted from blood samples by standard methods—in family 
1, DNA was only available from the affected son and unaffected 
parents; in family 2, DNA was available from both affected cases 
and their unaffected parents. Exome analysis was performed 
on the affected individual’s DNA (SureSelect Human All Exon 
50 Mb Kit, Agilent Technologies). Potentially pathogenic muta-
tions were identified by comparison with the GRCh37 reference 
human genome, filtering for changes with allele frequencies of 
<1 in 500 in the ExAC database (now incorporated within the 
genomAD database), and focused on homozygous and biallelic 
changes (and concordance between siblings in family 2). Novel 
unreported variants and known single- nucleotide polymor-
phisms (SNPs) were then sought that could be pathogenic by SIFT 
(missense variants) or by filtering (lost start and stop codons, 
premature nonsense variants, small insertions and deletions, and 
canonical splicing variants) in the exome results of the affected 
individuals of each family. A summary of the filtering process 
to discover potentially pathogenic variants in the two families 
is given in online supplemental table 1). Separately, all variants 
and SNPs in known holoprosencephaly genes were reviewed by 
hand. Any potential pathogenic variants were confirmed and 
tested for expected recessive segregation by PCR and Sanger 
sequencing of the parents and their affected offspring.
Microarray analysis seeking chromosome perturbations was 
performed in all four affected individuals. PLCH1 has three 
isoforms reported. We used the most common and longest tran-
script for our studies NM_001130960, which contains both of 
the mutations we report.
Re-examination of family genetic data seeking changes in 
holoprosencephaly-related genes
The following genes implicated are in SHH signalling and holo-
prosencephaly: BOC, CDON, DISP1, DHCR7, DLL1, FGF8, 
FOXH1, GAS1, GLI2, NODAL, PTCH1, SHH, SIX3, TDGF1, 
TGIF1, SUFU and ZIC2. All exons were adequately covered in 
our exome analysis for base changes and small INDELS.15 For 
these genes, we sought both novel variants and known SNPs 
that would be predicted as potentially pathogenic in the exomes 
of each family’s affected individuals. To find exon/gene scale 
deletions and duplications in these genes, we both re- exam-
ined microarray analyses of the affected children and examined 
Figure 1 Family pedigrees, summary phenotype table and brain scans 
of affected individuals. (A) Pedigrees of the two families described in the 
paper. Arrows show probands; filled- in squares or circles denote affected 
individuals; and red asterisks denotes people from whom we had a DNA 
sample. (B) Key phenotypical features of the affected four children aligned; 
all other family members have no disease features. A minus sign designates 
the feature was absent; a plus sign indicates it was present; and a triple 
plus sign indicates that the features were severe. (C,D) MRI brain scans 
of the two affected children from family 1, detailed in the text. For each, 
the top pair of scans shows results for 1 week of age, and the lower pairs 
for 39 weeks of age. (C) Gross hydrocephalus and the later findings were 
suggestive of holoprosencephaly. In both right- hand axial T2 views, the star 
shows the fused thalami, and two ventricular heteropias are best seen in 
the upper axial T2 view shown by arrow heads. (D) Lesser hydrocephalus 
with partial thalamic fusion, again a feature of the holoprosencephaly 
spectrum.
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sequencing depth by comparative analysis of affected versus 
controls in the Integrated Genome Viewer.
Gene cloning, tagging and mutagenesis of PLCH1
The plasmid pFLAG- CMV2 wild- type PLCH1 was manufactured 
from IMAGE clone IRATp970F03110D (Source BioScience) of 
PLCH1 isoform NM_001130960, generating pFLAG- PLCH1. 
The p.Cys1079ValfsTer16 variant was introduced into pFLAG- 
PLCH1 using the QuikChange mutagenesis (Stratagene, USA) 
protocol, using the following primers: (forward) 5′ CAGG AAAA 
CCCC TTCC CAGC AAGTC and (reverse) 5′ GACT TGCT GGGA 
AGGG GTTT TCCTG.
Subcellular localisation studies of PLCH1 and PLCH1 
p.(Cys1079ValfsTer16)
HEK 293 cells were grown in Dulbecco’s modified Eagle’s 
medium (Invitrogen), supplemented with 10% fetal calf serum, 
1% L- glutamine and 1% non- essential amino acids (Invitrogen). 
Cells were grown in a 95% air, 5% CO2 atmosphere at 37°C. 
Prior to transfection cells were plated to 60%–70% confluency 
on Poly- D- Lysine coated glass coverslips and transfected using 
Fugene HD (Promega) for 24 hours with four µg of pFLAG- 
PLCH1. All incubations were performed at room temperature 
and cells were analysed 72 hours post- transfection. Transfected 
cells were washed with PBS before and after a 10 min fixation 
with 4% paraformaldehyde and blocked in 10% donkey serum 
and 10% immunohistochemistry (IHC) blocking buffer (Sigma) 
diluted in PBS 0.1% Triton buffer (PBS- T) for 30 min. To detect 
PLCH1 variants tagged with FLAG, cells were incubated with 
rabbit anti- FLAG antibodies (Sigma) diluted 1:100 in PBS- T 
supplemented with 10% donkey serum for 2 hours. Cells were 
washed three times in PBS- T for 10 min before protein label-
ling with donkey anti- rabbit 488 antibodies (Invitrogen) diluted 
1:1000 in PBS- T for 45 min. Coverslips were washed before 
mounting using Fluromount- G DAPI (Invitrogen), and cells were 
viewed using the Zeiss LSM780 confocal microscope system.
IHC of PLCH1 expression in human embryos
The CS10, CS12 and CS13 human embryonic sections were 
provided by the Human Developmental Biology Resource, 
which is regulated by the Human Tissue Authority and operates 
in accordance with the relevant codes of practice. Embryos were 
collected from women undergoing social termination of preg-
nancy with appropriate maternal written consent and approval 
from the Newcastle and North Tyneside NHS Health Authority 
Joint Ethics Committee. The samples were staged using the 
guidelines of Bullen and Willson, fixed in methacarn (60% abso-
lute methanol, 30% chloroform and 10% glacial acetic acid) and 
processed through to paraffin wax (fibrowax, VWR).16 Sections 
were taken on a microtome at 7 μm thickness and mounted on 
Superfrost Plus microscope slides (Thermo Scientific).
Sections were dewaxed with Histo- Clear (National Diagnos-
tics), rehydrated in graded ethanol and rinsed in distilled water. 
Antigen retrieval was performed by heating the sections to 
95°C in sodium citrate buffer pH 6 for 20 min. Cooled sections 
were rinsed in distilled water before 2 and 5 min permeabi-
lisation washes in Tris–HCL 0.1% Triton buffer pH 10 (Tris–
HCL–T buffer). To prevent non- specific staining, sections were 
blocked in 10% donkey serum and 10% IHC blocking buffer 
(Sigma) diluted in Tris–HCL–T buffer for 90 min. Sections were 
incubated overnight at 4°C in a humidified chamber with rat 
polyclonal anti- SHH antibody (Abcam, ab50515) and rabbit 
polyclonal anti- human PLCH1 (Genetex, GTX108612), both 
diluted 1:100 in Tris–HCL–T buffer containing 10% donkey 
serum. After washing with Tris–HCL–T buffer, sections were 
labelled for 2 hours at room temperature with donkey anti- rabbit 
IgG-488 (Invitrogen) and donkey anti- rat IgG-546 (Invitrogen). 
Slides were washed with Tris–HCL buffer and mounted using 
Figure 2 PLCH1 gene and protein, with position of mutations, and subcellular localisation of PLCH1 wild type and family 2 mutation 
p.(Cys1079ValfsTer16). (A) Uppermost is a cartoon of the structure of the PLCH1 gene. The relative size of the exons, but not introns, is shown. Lowermost 
is a cartoon of the PLCH1 protein with the canonical PLCH domains in blue and named, a predicted nuclear localisation signal is shown in black, and 
predicted nuclear export signal in green. Between the gene and the protein, the family 1 and family 2 mutations are shown, with their respective postions 
in gene and protein indicated. (B) Electrophoretogram of the family 1 mutation, with upper homozygous wild- type control and lower homozygous mutation. 
(C) Subcellular localisation of wild- type PLCH1 on the left to be cytoplasmic in a transfected 1- 7HB2 epithelial cell line, whereas the middle pane shows 
that the family two mutation P. (Cys1079Valfs*16) is also present in the nucleus. on the right a bar chart shows the nuclear signal depicted by pixel/area 
of PLCH1 covered in the nucleus of WT PLCH1 (red) and mutant PLCH1 (blue). A two tailed t- test performed on the data gave a p value of 2.43116E-10, 
so p<0.01 and the mutant and WT PLCH1 nuclear signals are significantly different p<0.01, so mutant PLCH1 shows a statistically significant increase in 
nuclear signal. Methodology if needed for subcellular localisation of mut v wt: cellular localisation of the WT PLCH1 protein and mutant PLCH1 protein, 
showing a clear change in localisation to include in the nucleus in 1- 7HB2 epithelial cell line, with PLCH1 being stained with antiFLAG (goat anti- rabbit 488) 
in green at 1:1000 and DAPI nuclear staining in blue. These were viewed using confocal microscopy at ×100. PLCH1, phospholipase C eta-1.
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Fluromount- G DAPI (Invitrogen). Specimens were visualised 
using the Zeiss LSM780 confocal microscope system.
RESULTS
Clinical findings in the two families
Inheritance pattern: in each family there were both affected and 
unaffected children; the parents were unaffected (no features of 
the holoprosencephaly spectrum or other congenital anomalies 
or intellectual or neurological deficit); affected children were of 
both sex; parents were consanguineous (see figure 1A). There 
were no known affected individuals in the wider pedigrees. 
From this we concluded that the most likely inheritance pattern 
of the phenotypes in both families was autosomal recessive.
Full clinical phenotype details are given in the online supple-
mental file and summarised here and in figure 1B–D. In family 
1, the parents were Saudi first cousins and had three normal 
children. A 5- year- old boy, and in retrospect his deceased sister, 
were both affected and born with macrocephaly secondary 
to hydrocephalus. In the girl, postnatal brain MRI revealed a 
large posterior fossa cyst with atrophy of the cerebellum and 
partial agenesis of the vermis, heterotopias in both cerebral 
hemispheres, posteriorly kinked midbrain, atrophic pons, and a 
disfigured ventricular system giving the appearance of a mono-
ventricle with absent septum pellucidum. The later findings were 
suggestive of holoprosencephaly (see figure 1C). In the boy, a 
postnatal brain MRI at 1 week revealed a subependymal cyst 
near the foramen of Monro and partial agenesis of the corpus 
callosum. Repeat MRI at age 9 months showed partial thalamic 
fusion, evolving cerebral leucomalacia and apparent aqueduct 
stenosis (see figure 1D). Both children developed tonic–clonic 
epilepsy postoperatively and had gross motor and cognitive 
delay evident by 2 years. The girl also had a ventricular septal 
defect, cleft lip and palate (bilateral cleft lip and palate). In 
summary, both children had complex brain anomalies within the 
holoprosencephaly spectrum.
in family 2, the parents were Pakistani first cousins with two 
normal children. Their first affected child was a male infant who 
had alobar holoprosencephaly detected by antenatal ultrasound 
at 20 weeks of gestation. He was born at term but died shortly 
after birth. He was confirmed to have alobar holoprosencephaly 
and also cyclopia, a midline cleft lip, microcephaly (−3 SD) 
and cardiac anomalies (double outlet right ventricle, ventricular 
septal defect and possible aortic atresia). The parents declined 
postmortem examination. A second pregnancy, a woman, also 
had holoprosencephaly, with gross hydrocephalus. She also died 
a few hours after birth. She had no eyes but disrupted tissue 
beneath a proboscis, and her ears were joined together under 
her chin. The parents declined postmortem examination. In 
Figure 3 Human embryo immunohistochemistry studies expression of PLCH1 and SHH in a carnegie stage 10 sagittal section and carnegie stage 12 
transverse section through the upper thorax. Antibodies to human SHH are shown in red; antibodies to PLCH1 are shown in green; and DAPI in blue shows 
nuclei. (A) Near midline sagittal section of a CS10 embryo, with size bar 100 µm. The boxed area contains cells with both SHH and PLCH1 expression and is 
shown magnified in B. The green mass to the lower left is artefact autofluorescence. The orientation of the embryo is unclear, but probably the head is at the 
right top with the back at the bottom and abdominal area to the left side. (B) Magnification of the boxed area in A, size bar 40 µm. The upper left panel is 
of SHH expression, upper right of PLCH1, lower left of DAPI and the composite is at the lower right and shows a collection of cells, most of which express 
both SHH and PLCH1. (C) Transverse CS12 section through the upper thorax, with size bars 100 µm. The upper left panel is of SHH expression, upper right 
of PLCH1, lower left of DAPI and the composite is at the lower right showing the spinal cord at the centre including a boxed area, developing dorsal root 
ganglia at either side—on the right indicated by an arrow and laterally the somites stained prominently by PLCH1. (D) Magnification of the boxed area in C, 
size bar 25 µm. the left panel is of SHH expression, middle of PLCH1, and the composite is at the right also including DAPI. It shows that some cells in the 
developing spinal cord express SHH or PLCH1, but rarely both. (E) Magnification of the arrowed area in C, size bar 10 µm. The left panel is of SHH expression, 
middle of PLCH1, and the composite is at the right also including DAPI. This shows that the cells of the developing dorsal root ganglia predominantly 
express both SHH and PLCH1. PLCH1, phospholipase C eta-1; SHH, sonic hedgehog.
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summary, the babies both had a severe holoprosencephaly 
phenotype, and their diagnosis would include Young- Madders 
syndrome, SLOs or any of the single gene causes of holoprosen-
cephaly sequence—although the absence of polydactyly in both 
affected babies would be uncommon.17
Molecular genetic analysis seeking pathogenic variants
In both families, we analysed the exome data assuming a reces-
sive mode of inheritance, seeking both biallelic and homozygous 
pathogenic variants, and that were concordant between the 
affected individuals in family 2. No potential mutations were 
found in any known holoprosencephaly gene. There were no 
potential biallelic mutations in either family. Microarray analysis 
of affected individuals were normal.
Figure 2A shows PLCH1, the PLCH1 protein, and the vari-
ants found in each family. In family 1, we found a homozygous 
nonsense variant in the affected son, c.2065C>T in PLCH1, 
which leads to a premature stop codon p.(Arg689*) in exon 
16 (of 22 exons) and hence likely subject to nonsense mediated 
mRNA decay (see figure 2B). In family 2, a homozygous one 
base deletion in PLCH1 c. 3235delT was found, predicted to 
result in p.(Cys1079ValfsTer16). The deletion was in the last 
exon on PLCH1 and so would not be expected to be subject to 
nonsense mediated mRNA decay, but instead to yield a truncated 
protein with the C- terminal 623 amino acids (of 1693) deleted. 
Both of these mutations were confirmed as real, and to segregate 
as expected for a recessive genotype within families.
These PLCH1 variants have not been previously reported and 
are absent from gNOMAD.
Re-examination of family genetic data seeking changes in 
holoprosencephaly and SHH-related genes
In family 1 and family 2, we found no potential pathogenic 
variants in known SHH or holoprosencephaly- related genes. In 
family 1, PLCH1 variant was the only high- quality novel homo-
zygous coding variant with deleterious prediction identified 
within the autozygome of the index. In family 2, the following 
protein altering SNP genotypes were present in both affected 
babies: in DISP1 heterozygous rs2609383 p.(Glu103Lys) with 
global minor allele frequency (GMAF)=0.1814, and hetero-
zygous rs2789975 p.(Glu103Asp) with GMAF=0.1819; 
in NODAL homozygous rs1904589 p.(His165Arg) with 
GMAF=0.343; in CDON homozygous rs3740912 p.(Val75Ile) 
with GMAF=0.4525, heterozygous rs3740909 p.(Glu162Lys) 
with GMAF=0.1074 and homozygous rs684535 p.(Ile1221As) 
with GMAF=0.2002. In PTCH1 rs357564 p.(Pro1315Leu) 
with GMAF=0.390 was homozygous in one and heterozygous 
in the other. None of these SNPs is reported to have functional 
effects.
Subcellular localisation studies of PLCH1 and the PLCH1 
mutation p.(Cys1079ValfsTer16)
We found that wild- type PLCH1 was localised solely to the 
cytoplasm (see figure 2C). We had expected a nuclear localisa-
tion as a bipartite nuclear localisation motif was predicted to be 
present in PLCH1 (see figure 2A). The localisation of the mutant 
p.(Cys1079ValfsTer16) PLCH1 was either nuclear and cyto-
plasmic (25%), or only nuclear (75%) (see figure 2C). Therefore, 
Figure 4 Human embryo immunohistochemistry studies in carnegie stage 12 transverse sections illustrating a PLCH1 ventrodorsal gradient in the spinal 
cord, notocord expression and that embryonic subcellular localisation of PLCH1 is consistently cytoplasmic and not nuclear. Antibodies to human PLCH1 are 
shown in red, and DAPI in blue shows nuclei. (A) Transverse CS12 section through the upper thorax, with size bars 100 µm. Leftmost is PLCH1 expression; 
middle DAPI and the composite at right. This shows the ventrodorsal gradient of PLCH1 expression in the developing spinal cord – mirroring a similar 
reported SHH gradient. The laterally placed somites also express PLCH1. The dorsal root ganglia (between the somites and spinal cord) also express PLCH1 
but are less well shown. This is likely a consequence of the somites and spinal cord being continuous, but the dorsal root ganglia being an intermittent chain 
of cell aggregates. (B) Transverse CS12 section through the upper thorax, with size bars 100 µm; only staining for PLCH1 expression is shown. the white 
arrow shows PLCH1 expression in the notochord; the ventrodorsal gradient of PLCH1 expression in the developing spinal cord is again shown. (C) Sagittal 
C12 section with size bar 10 µm. Leftmost is PLCH1 expression, middle DAPI and the merge at right. This shows a cytoplasmic subcellular localisation of 
PLCH1 in the hindbrain. PLCH1, phospholipase C eta-1; SHH, sonic hedgehog.
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the pathogenic mechanism of the p.(Cys1079ValfsTer16) may be 
both of loss of the C- terminal domain, and also reduced protein 
availability at its site of action within critical cells. Furthermore, 
these results suggest the possibility that the PLCH1 nuclear 
localisation signal can be functional, and that the C- terminus of 
PLCH1 is able to block/mask this motif, potentially enabling the 
protein to change subcellular localisation. We found no evidence 
of PLCH1 expression in primary cilia using overexpression 
studies, in accord with published proteomics experiments (see 
online supplemental figure 1).18
Determination of the human embryonic expression pattern of 
PLCH1
Holoprosencephaly and the other developmental structural brain 
anomalies seen within the holoprosencephaly spectrum brain are 
thought to arise between human embryonic week 3 and embry-
onic week 5. This commences with human embryonic Carnegie 
stage 8, when the human midline notochord induces changes in 
the prechordal plate, which is anterior and lateral to the noto-
chord (the prechordal plate is destined to become the prosen-
cephalon, ultimately giving rise to all forebrain structures). By 
embryonic week 5, Carnegie stage 15, the prosencephalic struc-
tures, including the thalami, have formed, become distinct and 
separated.1 We did not attempt to perform a complete study of 
this developmental period, as the necessary embryo sections are 
unavailable.
The earliest embryo we were able to obtain was approximately 
Carnegie stage 10. SHH and PLCH1 both colocalise to the same 
small region of the embryo; both have a cytoplasmic subcellular 
localisation, but embryonic anatomical structures were impos-
sible to accurately define (see figure 3A,B).
Thereafter, the earliest embryo sections available were of 
Carnegie stage 12. We chose to examine a transverse sectioned 
Carnegie stage 12 embryo, a time- point when the spinal cord 
neural precursors are developing into different neuronal classes 
dependent on a dorsal bone morphogenic protein (BMP) 
gradient and a counter ventral SHH gradient. As expected, 
SHH is expressed in the spinal cord, acting as a control for the 
embryo age and anatomy (see figure 3C,D). We found PLCH1 
was also expressed with a clear ventral–dorsal gradient (greatest 
nearest the notochord; see figures 3C,D and 4A). Both SHH and 
PLCH1 are coexpressed in the developing dorsal root ganglia 
(identified by neutrophic tyrosine kinase receptor type 1 (TRKA) 
expression, results not shown; see figure 3E). PLCH1, but not 
SHH (as expected19), is expressed in the laterally placed somites, 
(see figures 3C and 4A). We also found SHH and PLCH1 present 
together in the notochord in transverse sectioned Carnegie stage 
12 embryo (figure 4B). Consistently, PLCH1 had a cytoplasmic 
subcellular localisation and is not seen in the nucleus, as best 
shown in the hindbrain in sagittal sectioned Carnegie stage 12 
embryo in figure 4C. The sections in figure 3 and figure 4A–C 
are each from different embryos.
These results show considerable colocalisation of PLCH1 
with SHH in the human embryonic nervous system. The results 
suggest that PLCH1 has more than one role in human embryonic 
development. The gradient of PLCH1 in the developing spinal 
cord is compatible with a role in neural precursor/early neurons 
being able to respond to SHH (as does the presence of PLCH1 
alone in somites). However, the presence of PLCH1 in the noto-
chord supports a role in SHH secretion.
DISCUSSION
We describe two families with a holoprosencephaly pheno-
type, one with extreme alobar holoprosencephaly and expected 
facial and cardiac malformations, the second with malforma-
tions restricted to the central nervous system (CNS). However, 
marked variability is common and expected in both dominant 
and recessive Mendelian diseases causing holoprosencephaly, 
and for this reason, we pursued the finding of homozygous vari-
ants in PLCH1 as being a possible novel Mendelian cause of the 
holoprosencephaly spectrum in these families.2 10 11
We first compared our cases to those of the best known reces-
sive diseases in which holoprosencephaly is a feature, SLOs and 
Young Madders syndrome (also known as pseudo- trisomy 13 
syndrome), sporadic Trisomy 13 and the dominant SHH muta-
tion phenotype20 (see table 1). Our cases are similar to those 
with Young- Madders syndrome and trisomy 13, but do exhibit 
the phenotypical variability seen in recessive SLOs and dominant 
SHH mutations. Severely affected SLOs individuals have only 
a few possible differences to our cases, the presence of 2/3 toe 
syndactyly, ambiguous genitalia, and polydactyly—all of which 
are extra- CNS anomalies.11 Young- Madders syndrome has the 
same phenotype as trisomy 13, with the karyotype distinguishing 
between the two.17 21 The gene causing Young- Madders syndrome 
has not been discovered (probably resulting in underascertain-
ment of more milder affected cases), although the only report 
of a consanguineous child in which homozygosity mapping was 
performed revealed 21 regions of homozygosity—one of which 
included PLCH122 (an a priori 10% chance23), so PLCH1 could 
be the cause of Young- Madders syndrome. The genes responsible 
for trisomy 13 phenotype are unclear, but polyalanine expan-
sions, deletions and a duplication of ZIC2 (on chromosome 13) 
Table 1 Comparison of the incidence of phenotype features of selected conditions in which holoprosencephaly is common from literature review*
Our cases† Smith- Lemli- Opitz syndrome Young- Madders syndrome Trisomy 13 SHH mutation phenotype
Mode of inheritance Recessive Recessive Recessive Sporadic dominant Autosomal dominant
Holoprosencephaly (%) 4/4 5 100‡ 30 36
Characteristic facies (%) >90 >90 >90 60 >60
Cleft lip (%) 3/4 40 53 40 20
Congenital heart disease (%) 3/4 50 15 80 2
Microcephaly (%) 1/4 80% 12 20 10
Male ambiguous genitalia (%) 0/2 50 60 0 5
Intellectual deficit range (%) 4/4 severe Normal (>5%) to severe 100% severe 100% severe Normal (30%) to severe
Postaxial polydactyly (%) 0/4 33 90‡ 80 <10
2/3 toe syndactyly (%) 0/4 >90 10§ 0§ 0§
*From the references in the text.
†As we describe four cases, we give numbers not a percentage.
‡Presumably a bias introduced by the disease definition.
§Presumably under- reported.
SHH, sonic hedgehog.
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have been reported in cases of holoprosencephaly without other 
known causes.24
The developmental processes that are considered to go awry 
in human holoprosencephaly occur between weeks 3 and 6 
postfertilisation. We therefore asked if there was evidence 
that PLCH1 was expressed in the human embryo during this 
period. While PLCH1 was considered to be expressed exclu-
sively in the CNS, there were no expression data available for 
this early period in human or murine embryos, and so we gener-
ated this.25 26 We used SHH as a marker of developmental stage 
and of early embryonic anatomy, and to see if PLCH1 and SHH 
were ever co- expressed. Results for a fourth- week embryo were 
limited to showing coincidence of expression of cytoplasmic 
PLCH1 and SHH in a contiguous region of cells, but we were 
unable to define the anatomy of the section. In fifth- week human 
embryo transverse sections of the upper thorax, we found that 
PLCH1 and SHH were both expressed in the developing spinal 
cord, the notochord and dorsal root ganglia. PLCH1 exhibited a 
ventral–dorsal gradient in the spinal cord, mimicking the known 
SHH morphogenic gradient, and the opposite of that of BMPs 
and WNTs. PLCH1 alone was detected in somites, which do not 
express SHH but respond SHH produced in the spinal cord. This 
data set is incomplete and, most importantly, we were not able 
to assess PLCH1 expression in the precordal plate (beginning 
of third week postfertilisation) as human embryonic samples 
were not available. However, we have shown SHH expression 
to be anatomically and developmentally as expected in the fifth 
week postfertilisation (as shown in our Carnegie stage 12 and 13 
results), and that PLCH1 and SHH have coincident expression 
in all neural tissues.
How could PLCH1 deficiency cause holoprosencephaly? 
Phospholipase C Eta-1 and Eta-2 (genes PLCH1 and PLCH2) 
are members of the most recently discovered class of the phos-
pholipase C family.27 As with all members of the phospholipase 
C family, on activation, PLCH1 increases intracellular calcium 
levels. As increases of intracellular calcium are necessary for 
SHH signalling, we hypothesised that PLCH1 could be one of 
the mediators of the calcium intracellular signal generated by 
SHH binding to its receptors.28 We speculate that PLCH1 has a 
role in the developmental responses to low levels of SHH, such 
as that generated by the spinal cord that then diffuses laterally 
to induce somite development. In holoprosencephaly, the SHH 
produced by the centrally placed caudal end of the notochord 
induces differentiation in the large prechordal plate, which grows 
caudally in all directions away from the notochord; hence, there 
will be a diminishing SHH gradient in outermost regions of the 
prechordal plate where we speculate PLCH1 to be expressed. 
Unfortunately, because of the unavailability of early human 
embryos (before Carnegie stage 10), we were unable to explore 
this. Taken together, our data suggest that PLCH1 could be a 
novel cause of autosomal recessive holoprosencephaly spectrum.
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